Biology Reference
In-Depth Information
Gray CM, Shapiro JM, Winters MA, et al. 1998. Changes in CD4 and CD8 T cell subsets in
response to highly active antiretroviral therapy in HIV type 1-infected patients with prior pro-
tease inhibitor experience. AIDS Res Hum Retroviruses 14: 561±569.
Hellerstein MK, McCune JM. 1997. T cell turnover in HIV disease. Immunity 7: 583±589.
Ho DD, Neumann AU, Perelson AS, et al. 1994. Rapid turnover of plasma virions and CD4 lym-
phocytes in HIV 1 infection. Nature 373: 123±126.
Ho HN, Hultin LE, Mittsuyasu RT, et al. 1993. Circulating HIV speci®c CD8 cytotoxic T cells
express CD38 and HLA-DR antigens. J Immunol 150: 3070±3079.
Kahn JO, Walker BD. 1998. Acute human immunode®ciency virus type 1 infection. New Engl J
Med 339: 33±39.
Kammerer R, Iten A, Frei PC, Burgisser P. 1996. Expansion of T cells negative for CD28 expres-
sion in HIV infection. Med Microbiol Immunol 185: 19±25.
Katsikis PD, Wunderlich ES, Smith CA, et al. 1995. Fas antigen stimulation induces marked
apoptosis of T lymphocytes in human immunode®ciency virus-infected individuals. J Exp Med
181: 2029±2036.
Kaufman D, Pantaleo G, Sudre P, et al. 1998. CD4 cell count in HIV-infected individuals remain-
ing viraemic with highly active antiretroviral therapy (HAART). Lancet 351: 723±724.
Kelleher AD, Carr A, Cooper DA. 1996. Alterations in the immune response of HIV-infected sub-
jects treated with an HIV-speci®c protease inhibitor, Ritonavir. J Infect Dis 173: 321±329.
Kelleher AD, Al-Harti L, Landay AL. 1997. Immunological e¨ects of antiretroviral and immune
therapies for HIV. AIDS 11: S149±S154.
Kestens L, Vanham G, Vereecken C, et al. 1994. Selective increase of activation antigens HLA-DR
and CD38 on CD4 CD45RO T lymphocytes during HIV-1 infection. Clin Exp Immunol 95:
436±441.
Legac E, Autran B, Merle-Beral H, et al. 1992. CD4 CD7 ÿ CD57 T cells: a new T lymphocyte
subset expanded during HIV infection. Blood 79: 1746±1753.
Lenkei R, Bratt G, Holmberg V, et al. 1998. Indicators of T-cell activation: correlation between
quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV individuals and
healthy controls. Cytometry 33: 115±122.
Levy JA. 1993. HIV pathogenesis and long-term survival. AIDS 7: 1401±1410.
Loetscher P, Moser B, Baggiolini M. 2000. Chemokines and their receptors in lymphocyte tra½c
and HIV infection. Adv Immunol 74: 127±180.
Mahalingam M, Peakman M, Davies ET, et al. 1993. T cell activation and disease severity in HIV
infection. Clin Exp Immunol 93: 337±343.
Mahalingam M, Pozniak A, McManus TJ, et al. 1995. Cell cycling in HIV infection: analysis of in
vivo activated lymphocytes. Clin Exp Immunol 102: 481±486.
Martinon F, Michelet C, Peguillet, Taou®k Y, Lefebvre P, Goujard C, Guillet J, Delfraissy J, Lantz
O. 1999. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene ex-
pression after 1 year of highly active antiretroviral therapy. AIDS 13: 185±194.
McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. 1995. Expression of the Fas antigen on patients
infected with HIV. Cytometry 22: 111±114.
Medrano FJ, Leal M, Arienti D, et al. 1998. Tumor necrosis factor beta and soluble APO-1/Fas
independently predict progression to AIDS in HIV-seropositive patients. AIDS Res Hum
Retroviruses 14: 835±843.
Meroni L, Fusi ML, Varchetta S, et al. 1999. Altered signaling lymphocytic activation molecule
(SLAM) expression in HIV infection and redirection of HIV-speci®c responses via SLAM trig-
gering. Clin Immunol 92: 276±284.
Miyawaki T, Uehara T, Nibu R, et al. 1992. Di¨erential expression of apoptosis-related Fas anti-
gen on lymphocytes subpopulations in human peripheral blood. J Immunol 149: 3753±3758.
Search WWH ::




Custom Search